Drug search by name

Foscarnet and Electrolyte disturbances

Result of checking the interaction of drug Foscarnet and disease Electrolyte disturbances for safety when used together.

Check result:

Foscarnet <> Electrolyte disturbances

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Foscarnet may cause electrolyte disturbances, including hypocalcemia, hypo- or hyperphosphatemia, hypomagnesemia, and hypokalemia. Ionized serum calcium may also demonstrate a dose-dependent (and possibly rate-dependent) decrease that may not be reflected in total serum calcium. Patients should be instructed to report symptoms of low ionized calcium such as perioral tingling, numbness in the extremities, and paresthesias. Other electrolyte-related complications include tetany, seizures, and cardiac disturbances. Therapy with foscarnet should be administered cautiously in patients with preexisting fluid and electrolyte imbalance and those with underlying cardiac or neurologic abnormalities. Serum electrolyte levels should be closely monitored and managed in all patients treated with foscarnet.

References:

Conn J, Colman P, Brown G, Street A, Bate K "Nephrogenic diabetes insipidus associated with foscarnet - a case report." J Antimicrob Chemother 37 (1996): 1179-81
Jacobson MA, Gambertoglio JG, Aweeka FT, et al "Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism." J Clin Endocrinol Metab 72 (1991): 1130-5
Malin A, Miller RF "Foscarnet-induced hypokalaemia." J Infect 25 (1992): 329-30
"Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29
Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361
Gearhart MO, Sorg TB "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders." Ann Pharmacother 27 (1993): 285-9
Brown DL, Sather S, Cheitlin MD "Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient." Am Heart J 125 (1993): 1439-41
Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73
Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87
Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
Blanshard C "Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet." J Acquir Immune Defic Syndr 5 (1992): s25-8